Compare Abeona Therapeutics Inc (ABEO) vs Centene Corp (CNC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Centene Corp — how do they compare? Abeona Therapeutics Inc trades at $6.71 (market cap $373.32M), while Centene Corp trades at $67.57 (market cap $32.65B). The key difference: Centene Corp is far larger — about 87.5× Abeona Therapeutics Inc's market cap, and Centene Corp is trading nearer its 52-week high, Abeona Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | CNC | |
|---|---|---|
Market Cap | $373.32M | $32.65B |
Sector | Health | Health |
52-Week High | $7.23 | $68.34 |
52-Week Low | $4.17 | $25.21 |
Enterprise Value | $228.22M | $25.28B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Centene (CNC) trades at $66.12, down 2.56% on the day, with a bullish technical signal from moving averages despite recent weakness. The stock shows attractive valuation ratios (P/E 8.06, P/S 0.16) but faces profitability challenges with negative net income margin (-3.25%) and ROE (-26.12%). Recent earnings beats and strong analyst support (62.79% buy ratings) contrast with operational headwinds in Medicaid margins and cost pressures.
Investment outlook balances deep value against execution risks. The consensus price target of $63.29 suggests limited upside, but improving cash flow trends and AI-driven cost initiatives could support recovery. Key risks include regulatory changes, adverse selection in insurance pools, and margin sustainability amid healthcare sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Centene Corp
Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of September 2021, mostly in Medicaid (68% of membership), the individual exchanges (10%), Medicare Advantage (6%), and the balance in Tricare (West region), correctional facility, and international plans. The company also serves 4 million users through the Medicare Part D pharmaceutical program.
Read more on CNC →
